Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (CTRI/2026/10/119296) titled 'A post marketing surveillance study to evaluate the safety and effectiveness of semaglutide in adults with overweight or obesity in routine clinical practice' on Oct. 9.
Study Type: PMS
Study Design:
Single Arm Study Method of generating randomization sequence:Not Applicable Method of allocation concealment:Not Applicable Blinding and masking:Not Applicable
Primary Sponsor: Novo Nordisk India Private Limited
Condition:
Health Condition 1: E669- Obesity, unspecified
Health Condition 2: E668- Other obesity
Health Condition 3: E663- Overweight
Intervention:
Intervention1: NIL: NIL
Intervention2: NA: ...